Results 31 to 40 of about 19,474 (223)

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Cancer Cell, 2023
SUMMARY Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating feasibility and safety of
Sabina Kaczanowska, Tara Murty, A. Alimadadi, Cristina F. Contreras, Caroline Duault, Priyanka B. Subrahmanyam, Warren D. Reynolds, Norma A. Gutierrez, Reema Baskar, Catherine J. Wu, Franziska Michor, J. Altreuter, Yang Liu, Aashna Jhaveri, Vandon Duong, H. Anbunathan, C. Ong, Hua Zhang, Radim Moravec, Joyce Yu, Roshni Biswas, Stephen C. Van Nostrand, James R. Lindsay, Mina Pichavant, E. Sotillo, Donna B. Bernstein, A. Carbonell, J. Derdak, Jacquelyn Klicka-Skeels, Julia E. Segal, E. Dombi, S. Harmon, B. Turkbey, B. Sahaf, Sean C. Bendall, H. Maecker, S. Highfill, David F. Stroncek, J. Glod, Melinda S. Merchant, C. Hedrick, Crystal L. Mackall, S. Ramakrishna, R. Kaplan   +43 more
semanticscholar   +1 more source

In vitro Vergleich bispezifischer GD2-Antikörperkonstrukte und GD2-CAR-T Zellen gegen Neuroblastomzelllinien [PDF]

, 2022
Das Neuroblastom ist der häufigste, solide, extrakranielle Tumor im Kindesalter. Trotz umfassender Forschung beträgt die Überlebensrate im Hochrisikostadium nur ca. 50%.
Paasburg, Nadia
core  

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

Journal for ImmunoTherapy of Cancer, 2021
Background The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting
Stefan Nierkens, Niels Eijkelkamp, Maaike Nederend, Jeanette Leusen, Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Marco Jansen, Chilam Chan, Kevin Budding, Thomas Valerius, Friederike Meyer-Wentrup   +12 more
doaj   +1 more source

Differential roles of gangliosides in malignant properties of melanomas. [PDF]

PLoS ONE, 2018
Ganglioside GD3 is widely expressed in human malignant melanomas, and has been reported to be involved in the increased cell proliferation and invasion.
Yuhsuke Ohmi, Mariko Kambe, Yuki Ohkawa, Kazunori Hamamura, Orie Tajima, Rika Takeuchi, Koichi Furukawa, Keiko Furukawa   +7 more
doaj   +1 more source

Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin

Pharmaceutics, 2022
Disialoganglioside (GD2) is a subtype of glycolipids that is highly expressed in tumors of neuroectodermal origins, such as neuroblastoma and osteosarcoma.
Fuyuki F. Inagaki, Takuya Kato, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   +8 more
doaj   +1 more source

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells

Journal for ImmunoTherapy of Cancer, 2021
Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no effective standard therapy. Breast cancer stem-like cells (BCSCs) in primary TNBCs are reported to be responsible for metastatic spread of the disease ...
Debasish Tripathy, Khoa Nguyen, Stanley Ly, Vivek Anand, Fouad El-Dana, Yiming Cai, Shirong Cai, Helen Piwnica-Worms, Aysegul A Sahin, Michael Andreeff, Venkata Lokesh Battula   +10 more
doaj   +1 more source

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Nature Medicine
In a phase 1 clinical trial open to accrual from 2004 to 2009, we treated children with neuroblastoma with Epstein–Barr virus (EBV)-specific T lymphocytes and CD3-activated T cells—each expressing chimeric antigen receptors (CARs) targeting GD2 but ...
Che-Hsing Li, Sandhya Sharma, A. Heczey, M. Woods, David H. M. Steffin, Chrystal U. Louis, B. Grilley, Sachin G. Thakkar, Mengfen Wu, Tao Wang, C. Rooney, Malcolm Brenner, Helen E. Heslop   +12 more
semanticscholar   +1 more source

gD2-specific cellular immune responses.

, 2019
Responses to gD2 were determined using PBMCs collected at baseline (week 0), after immunisation (week 9), before booster (week 24) and after booster (week 25).
Julie L. Dutton (8138424), Neil Finlayson (8138430), Sally Kinrade (8138427), Julian Druce (4520320), David M. Koelle (8138436), Ian H. Frazer (7418663), Yan Xu (14594), Paul Griffin (3387026), Janin Chandra (3215100), Bo Li (112195), Wai-Ping Woo (466117), Kerry J. Laing (8138433)   +11 more
core   +1 more source

gD2-specific cellular immune responses to COR-1.

, 2019
Responses to gD2 were determined using PBMCs collected at baseline (week 0), after immunisation (week 9), before booster (week 24) and after booster (week 25).
Julie L. Dutton (8138424), Neil Finlayson (8138430), Sally Kinrade (8138427), Julian Druce (4520320), David M. Koelle (8138436), Ian H. Frazer (7418663), Yan Xu (14594), Paul Griffin (3387026), Janin Chandra (3215100), Bo Li (112195), Wai-Ping Woo (466117), Kerry J. Laing (8138433)   +11 more
core   +1 more source

Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation [PDF]

, 2011
High-risk neuroblastoma is one of the most common deaths in pediatric oncology. Current treatment of this disease involves a coordinated sequence of chemotherapy, surgery, and radiation.
Ching-An Peng, Chung-Hao Wang, Peng, Ching-An, Wang, Chung-Hao   +3 more
core   +1 more source